Iris Löw-Friedrich
Chief Executive Officer bei ZOGENIX, INC.
Profil
Dr. Iris Lw-Friedrich ist stellvertretende Aufsichtsratsvorsitzende bei Evotec SE, Chief Medical Officer & Executive Vice President bei UCB SA und Professorin an der Johann Wolfgang Goethe-Universität Frankfurt am Main. Sie ist Mitglied des Verwaltungsrats der Fresenius SE & Co. KGaA und Evotec SE. Dr. Lw-Friedrich war zuvor als Chairman bei Transcelerate Biopharma, Inc. beschäftigt, als Mitglied des Aufsichtsrats bei Heidelberg Pharma AG, als Director-Research & Development bei UCB Pharma GmbH, als Vice President-Global Projects bei BASF Pharma, als Vice President-Global Projects bei BASF AG, als Vice President-Clinical Development bei Hoechst AG, als Head-Global Clinical Management & VP bei Aventis Pharma AG und als Vice President-Clinical Development bei Hoechst Marion Roussel, Inc. Sie promovierte an der Johann Wolfgang Goethe-Universitt Frankfurt am Main.
Aktive Positionen von Iris Löw-Friedrich
| Unternehmen | Position | Beginn |
|---|---|---|
| UCB | Chief Tech/Sci/R&D Officer | 01.03.2008 |
| EVOTEC SE | Chairman | 15.06.2021 |
| FRESENIUS SE & CO. KGAA | Director/Board Member | 13.05.2016 |
| ZOGENIX, INC. | Chief Executive Officer | - |
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Corporate Officer/Principal | 01.01.2000 |
PhRMA Foundation
 PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Director/Board Member | 01.04.2019 |
Ehemalige bekannte Positionen von Iris Löw-Friedrich
| Unternehmen | Position | Ende |
|---|---|---|
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Chairman | 01.09.2017 |
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Chief Tech/Sci/R&D Officer | 01.01.2009 |
| BASF SE | Corporate Officer/Principal | 01.01.2001 |
| ░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Iris Löw-Friedrich
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| FRESENIUS SE & CO. KGAA | Health Technology |
| BASF SE | Process Industries |
| UCB | Health Technology |
| EVOTEC SE | Health Technology |
| HEIDELBERG PHARMA AG | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
UCB Pharma GmbH
UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
| Aventis Pharma AG | |
| Hoechst Marion Roussel, Inc. | |
| BASF Pharma | |
PhRMA Foundation
PhRMA Foundation Miscellaneous Commercial ServicesCommercial Services The PhRMA Foundation is an organization that provides awards and support to individuals pursuing higher education. The non-profit company is based in Washington. The organization's 2022 annual report highlights their activities and showcases their 2022 awardees. | Commercial Services |
Transcelerate Biopharma, Inc.
Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Health Technology |
